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Summary 
Aim(s) 
Leflunomide, via its active metabolite teriflunomide, is used in rheumatoid arthritis (RA) 
treatment, yet approximately 20 to 40% of patients cease due to toxicity. The aim was to 
develop a time-to-event model describing leflunomide cessation due to toxicity within a 
clinical cohort and to investigate potential predictors of cessation such as total and free 
teriflunomide exposure and pharmacogenetic influences. 
Methods 
This study included individuals enrolled in the Early Arthritis inception cohort at the Royal 
Adelaide Hospital between 2000 and 2013 who received leflunomide. A time-to-event model 
in NONMEM was used to describe the time until leflunomide cessation and the influence of 
teriflunomide exposure and pharmacogenetic variants. Random censoring of individuals was 
simultaneously described. The clinical relevance of significant covariates was visualised via 
simulation. 
Results 
Data from 105 patients was analysed, with 34 ceasing due to toxicity. The baseline dropout 
hazard and baseline random censoring hazard were best described by step functions changing 
over discrete time intervals. No statistically significant associations with teriflunomide 
exposure metrics were identified. Of the screened covariates, carriers of the C allele of 
CYP1A2 rs762551 had a 2.29 fold increase in cessation hazard compared to non-carriers 
(95% CI 2.24 - 2.34, p=0.016). 
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Conclusions 
A time-to-event model described the time between leflunomide initiation and cessation due to 
side effects. The C allele of CYP1A2 rs762551 was linked to increased leflunomide toxicity, 
while no association with teriflunomide exposure was identified. Future research should 
continue to investigate exposure-toxicity relationships, as well as potentially toxic 
metabolites. 
What is already known about this subject 
 Leflunomide is an effective treatment option in RA yet approximately 20 to 40% of 
patients fail due to toxicity. 
 Teriflunomide’s pharmacokinetics are highly variable, yet total concentrations have 
not been linked to toxicity, despite an association with response. 
 Polymorphisms within CYP1A2, CYP2C19 and DHODH have previously been linked 
to toxicity. 
What this study adds 
 A time-to-event model that included random censoring was developed that simulated  
cessation of leflunomide due to side effects in RA patients.  
 Predicted total and free teriflunomide steady-state trough concentrations were not 
associated with toxicity. 
 The instantaneous cessation hazard increased 2.29 fold in carriers of the C allele of 
CYP1A2 rs762551. 
 This article is protected by copyright. All rights reserved. 
Introduction 
Leflunomide is a disease modifying antirheumatic drug (DMARD) used in the treatment of 
rheumatoid arthritis (RA), a chronic inflammatory autoimmune disease associated with 
severe morbidity, reduced functional ability and increased mortality[1]. Meta-analyses have 
shown that leflunomide has comparable efficacy to methotrexate, the gold standard for RA 
treatment[2, 3], and leflunomide is commonly used as a second line therapy option either as 
monotherapy or in combination with other conventional DMARDs in patients with resistant 
disease[4-6]. However, a major limitation for achieving remission with leflunomide is that up 
to 40% of patients discontinue therapy due to toxicity[2, 7, 8].  Gastrointestinal side effects 
(e.g. diarrhoea, nausea and vomiting; GI) are experienced by 20-30% of patients and are most 
likely to occur early in treatment and may settle if patients persist with therapy[8, 9]. In those 
who do not adequately respond to conventional DMARDs, biological DMARDs are 
considered[4-6]. In addition to being associated with an increased incidence of some cancers 
and serious infections[10], these agents are costly, so maximising remission rates with less 
expensive therapies such as leflunomide is likely to be a worthwhile strategy to maintaining 
patient outcomes whilst reducing the financial burden association with biological agents.  
Cytochrome P-450 enzymes (CYP) -1A2, -2C19 and 3A4 are responsible for the metabolism 
of leflunomide to teriflunomide (the active metabolite), and previous studies have shown that 
genetic polymorphisms in CYP1A2 and CYP2C19 may be linked to increased toxicity[11, 
12]. Furthermore, polymorphisms in CYP2C19 have been associated with altered plasma 
concentration, but to date no association of concentration with CYP1A2 genotype or smoking 
has been seen[13]. A single nucleotide polymorphism (SNP) within the first exon of 
dihydroorotate dehydrogenase (DHODH, rs3213422, 19C>A), the primary target of 
teriflunomide, has also been linked to increased toxicity[14]. Previous cross-sectional studies 
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have identified a relationship between total teriflunomide concentrations and leflunomide 
response in patients with RA, but no relationship with adverse drug events has been 
identified[13, 15, 16]. Plasma teriflunomide is highly bound to plasma proteins (>99%)[17], 
and for many drugs with a high degree of protein binding, total concentrations may be a poor 
surrogate of the free concentrations which are responsible for exerting clinical effects[18]. 
Studies have indicated variability between total and free teriflunomide concentrations[19, 
20], but as yet free concentrations have not been investigated for a link to toxicity or response 
in RA patients. 
The aim of this study was to develop a time-to-event model[21] describing the cessation of 
leflunomide due to toxicity, and to investigate potential predictors of this outcome including 
total and free teriflunomide exposure and pharmacogenetic markers. 
Methods 
Software 
Modelling was performed using a Dell® Power Edge R910 server with 4x10 core Xeon 2.26 
Ghz processors and 256 GB of RAM running Windows Server 2008 R2 Enterprise with a 64-
bit operating system. Time-to-event model development was performed using NONMEM® 
Version VII Level 2.0 (Beal et al. 2009, ICON Dev. Soln., Ellicott City, MD) with the Wings 
for NONMEM (Version 720) interface (http://wfn.sourceforge.net/) and the G95 Fortran 
compiler. 
Data manipulation, steady state concentration prediction, Kaplan-Meier analysis and survival 
model graphical output were conducted with the R Software Version 3.1.1 (R Core Team 
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2014) using the ggplot2, doBy, stringr, Hmisc, plyr, reshape2, gridExtra, scales, deSolve   
and survival  packages[22-31]. 
Study population 
Participants were aged ≥18 years, diagnosed with DMARD-naïve RA according to revised 
ACR Criteria[32] and enrolled in the RA inception cohort at the Royal Adelaide Hospital 
(RAH) between 2000 and 2013. Exclusion from the study included insufficient clinical 
records during the follow up period. All participants were treated according to a previously 
published treat-to-target protocol[6]. At diagnosis ‘triple therapy’ (methotrexate, 
sulfasalazine and hydroxychloroquine) was initiated. Patients were generally assessed every 
six weeks during active disease, or every three months once disease was inactive. If RA was 
active according to pre-defined criteria[6], sulfasalazine and then methotrexate were up-
titrated to maximum tolerated doses. If this failed to control disease, leflunomide was added. 
During the first three years of the cohort study, leflunomide was initiated with a loading dose 
(three daily doses of 100 mg followed by 20 mg daily). Subsequently, this practice changed 
to an initial daily dose of 10 mg, and in the case of persistent disease, the daily dose was 
increased to 20 mg. Patients gave informed written consent for inclusion in the inception 
cohort and provision of a DNA sample. Ethics approval was obtained from the Human 
Research Ethics Committee of the RAH and the University of South Australia.  
Event time data 
Study participants were followed for up to 60 weeks after leflunomide initiation. Participants 
either i) continued to take leflunomide throughout the study period and were censored at the 
clinic visit date ‘closest’ to 52 weeks, or if the closest’ visit date was greater than 52 weeks, 
were censored from the study at 52 weeks ii) had another DMARD added (due to persistent 
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disease activity) during the 60 week study period and were not considered to have ceased 
leflunomide due to side effects, but were censored at the date this new DMARD was added, 
or iii) ceased leflunomide due to side effects before 52 weeks. Treating clinicians were 
responsible for determining and recording the date of leflunomide cessation due to toxicity, 
with causality confirmed via a Naranjo categorisation of possible or greater[33].  
At initiation of leflunomide, age, gender, smoking status, use of other DMARDs, leflunomide 
initiation dose and DAS28 were recorded, as was anti-cyclic citrullinated peptide antibody 
(anti-CCP), rheumatoid factor (RF) and shared epitope (SE) status at RA diagnosis. Missing 
values for continuous and categorical covariates were imputed with the median or mode 
respectively. At the individual’s cessation or censor dates, height, weight, other DMARD 
doses, albumin, bilirubin, creatinine clearance (CrCl; Cockcroft-Gault Equation – IBW) and 
liver function test results were recorded. The fat free mass (FFM; based upon total body 
weight, height and sex[34]) was also calculated for individuals at these dates. Missing values 
for continuous and categorical covariates at the cessation or censor date were imputed, via 
forward inclusion, from the previous visit. DHODH haplotype, DHODH rs3213422 (C19A) 
genotype, PTPN22 rs2476601 (C1858T) genotype, CYP1A2 rs762551 (C163A) genotype, 
predicted CYP2C19 ‘phenotype’ and ABCG2 rs2231142 (C421A) genotype had all been 
determined prior to this study as described previously[12, 35, 36]. Predicted CYP2C19 
‘phenotype’ was determined from rs4244285 and rs12248560 genotypes, and individuals 
were characterised as either unknown, ultra-rapid, extensive or poor and intermediate 
metabolisers, with unknown metabolisers imputed with the mode[12]. Haplotype, genotype 
or ‘phenotype’ grouping was conducted in the event of low allele frequencies (i.e. carriers of 
a homozygous recessive genotype with a frequency <10% were grouped with the 
heterozygous genotype). 
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Exposure metrics 
Between 2010 and 2013, 69 participants involved in this study additionally gave informed 
written consent for collection of blood samples used to determine total and free teriflunomide 
concentrations, as previously described by Rakhila et al.[20]. Participants on a stable dose of 
leflunomide provided 2x10 mL blood samples collected at successive clinical visits 
(generally 6-12 weeks apart). Participants who initiated leflunomide between 2010 and 2013, 
had a blood sample collected before the first dose, followed by another at each of their next 5 
clinic visits. All blood samples were collected as pre-dose trough samples. 
For this data set, a semi-physiological pharmacokinetic model describing individual total and 
free teriflunomide concentrations, teriflunomide clearance (CLINT), volume of distribution 
(VBODY) and fraction unbound (FU) was developed[37]. From this model, empirical Bayes 
estimates of the physiological parameters controlling total and free teriflunomide 
concentrations were determined for each individual at their cessation or censor date. For 
individuals from whom no blood samples had been collected, physiological parameter 
estimates were imputed with the population median, as influenced by the individuals FFM 
and ALT concentrations[37]. Using the posteriori Bayes parameter estimates and the deSolve 
package of R, total and free teriflunomide steady state trough concentrations were predicted 
for each individual after 365 consecutive daily doses at the individual’s average daily dose 
given across the study period. The average daily leflunomide dose across the study period 
and model predicted FU, CLINT and VBODY were also assessed as possible predictors of 
toxicity. 
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Structural model development 
The time to leflunomide cessation due to toxicity was described by a time-to-event model 
developed in a stepwise manner where (i) a base model without any explanatory factors, apart 
from time, was built and (ii) the effect of potential covariates on the rate of leflunomide 
toxicity were investigated. 
The likelihood of not having ceased leflunomide due to toxicity at time t, was described by 
the parametric survival function, S(t).  
               
 
  Equation 1 
Where h(t) is the instantaneous hazard rate at time t, and S(t) is a function of the cumulative 
hazard function, H(t), between time zero and time t. 
              
 
 
 Equation 2 
As time-to-event models only use one observation for each individual, random effects on the 
baseline hazard could not be estimated, i.e. the same baseline hazard is assumed for all 
subjects. The probability density, f(t), of ceasing leflunomide at time t, was described by: 
                 Equation 3 
Base models were developed by exploring different functions for base hazards, h0(t), starting 
with a constant hazard, then Weibull, Gompertz, log-logistic distributions and finally, step 
functions. Selection of the base model was guided by visualisation of the estimated survival 
curve against a raw data Kaplan-Meier plot, as well as the change in Objective Function 
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Value (OBJ) as indicated by the lowest value of the Akaike’s information criterion (AIC), 
where: 
                                 Equation 4 
Equation 5 gives an example of a step function where the baseline hazard h0(t) changed 
depending on the time.  
         
            
              
               
  Equation 5 
A step function of this type was explored by starting with a single constant, and increasing 
the number of steps until no decrease in the AIC was observed. The time cut-offs for the steps 
were chosen based on the shape of a Kaplan-Meier plot of the raw data. 
In order to facilitate simulation (see below), the random censoring of individuals before day 
365 (e.g. cessation of leflunomide for reasons other than toxicity, having another DMARD 
added due to insufficient response or less than 365 days of follow-up) was also 
simultaneously described by a time-to-event model with its own h0ran(t), Sran(t), Hran(t) and 
fran(t). 
Covariate model development 
Covariates were screened according to biological plausibility and prior knowledge of the 
factors considered to influence leflunomide toxicity. Covariates were included within 
functions (λcov) developed to modify the base hazard, h0(t), to give the hazard function, h(t): 
                           Equation 6 
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Categorical variants were assessed through a binary relationship (Equation 7), while 
continuous covariates were included as exponential functions normalised by the median 
covariate value (Equation 8). Concomitant drug effects were investigated via a linear function 
with their dose (Equation 9). 
                       Equation 7 
       
   
   
         
 
 Equation 8 
            
       
         
  Equation 9 
The potential inclusion of covariates on the base model were selected based upon a 
significant decrease in OBJ (p<0.05). The final model was developed via forward inclusion, 
where each covariate was sequentially added, starting with the covariate that caused the 
largest drop in the OBJ, and the following covariate(s) were only retained if the selection 
criteria were met. 
Model evaluation and simulation 
For the final structural and covariate models, nonparametric bootstrap analysis was used to 
assess the uncertainty of the parameter estimates. The original dataset was resampled 1000 
times and analysed to estimate the 95% confidence intervals (95% CI) of the model 
parameters. 
Time-to-event model visual predictive checks were used to assess the ability of  the final 
structural and covariate models to describe the data[21, 38]. Using the R survival package, 
the survival probability of 1000 simulated replicate populations was computed at half daily 
intervals. The median and 95% CI of these survival probabilities were visually compared 
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against the Kaplan-Meier plot with 95% CI of the original dataset. To enable simulation, 
daily intervals from 1 to 365 were added to the original data for each individual. Covariate 
information was added to these additional records by a last observation carried 
forward/previous observation carried backward approach. The probability that an individual 
would be randomly censored (Equation 10) or cease leflunomide due to toxic effects 
(Equation 11) during an interval (i.e. a day) were respectively represented by conditional 
probabilities of failure,        
           
  : 
        
   
                 
        
 Equation 10 
     
   
           
     
 Equation 11 
In NONMEM, the conditional probabilities of random censoring and cessation were 
compared against two randomly generated uniform numbers between 0 and 1, representing 
the individual’s probability of remaining in the study or ceasing leflunomide during that time 
period. If at time t2,     
   was greater than the corresponding random number, the individual 
was said to have ceased leflunomide if they had not previously been lost to follow up due to a 
random censoring occurrence (i.e. had at a previous time        
   been greater than its 
corresponding random number). 
Results 
Patients 
A total of 115 patients commenced leflunomide and 10 were excluded due to incomplete 
records, leaving 105 participants available for analysis. Their baseline characteristics and 
teriflunomide exposure metrics are described in Table 1. 
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Of the 105 patients, 34 (32.4%) ceased leflunomide due to toxicity before day 365 of 
treatment. The side effects that contributed to the cessation of leflunomide are indicated in 
Table 2. Censoring from the study before day 365 occurred in 3 (2.9%) patients due to 
leflunomide cessation not related to toxicity, 9 (8.6%) due to inadequate response resulting in 
another DMARD being initiated, while in 33 (31.4%) patients, the closest clinic date to study 
completion was before day 365. The final clinic visit between day 365 and 420 occurred in 
26 (24.8%) patients. 
Two baseline DAS28 were missing from the data set and these were imputed with the 
median.  RF, anti-CCP and SE status were imputed with the mode for one, two and four 
participants respectively, while CYP2C19 phenotype[12] was unpredictable for eight 
individuals, who were similarly imputed with the mode. Blood samples were only available 
from 69 of the 105 participants, and thus participants with no samples had physiological 
parameter estimates that were imputed with the median as adjusted for the individuals ALT 
and FFM. These parameter estimates were used to predict the individuals total and free 
steady state trough teriflunomide concentration based upon their average leflunomide dose. 
Structural model 
The hazard functions h0(t) and h0ran(t) that best described the data with regards to AIC and 
visualisation against the original dataset Kaplan-Meier plot were step functions. For h0(t), 
results were best described by four time intervals, each with its own constant hazard rate, 
whereas h0ran(t) was best described by five time intervals. The resulting cessation hazard, 
h0(t), was high for the first 50 days, followed by a lesser decrease until day 112, after which it 
was higher until day 204, before another lesser decrease until the end of the study period. 
Conversely random censoring hazard, h0ran(t), increased significantly when comparing the 
first time interval against the final (Table 3). 
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Covariate model 
Of the screened covariates, only CYP1A2 C163A allele status met the inclusion criteria and 
no teriflunomide exposure covariates were identified (Table 4).  
The 51 carriers of the C allele at CYP1A2 C163A (i.e. CC or CA genotype) had a 2.29 fold 
(95% CI = 2.24 - 2.34) increase in cessation hazard compared to the 54 A homozygotes. The 
OBJ (1036.75) was 5.80 lower than with the structural model (p=0.016). Parameter estimates 
of the covariate model and the precision of these estimates are represented in Table 3. 
Figure 1 (top) shows good concordance between the Kaplan-Meier plot of the observed 
population data against the median and associated 95% CI of the simulated survival data from 
the covariate model. Similarly, Figure 1 (bottom) shows good agreement between the 
observed and simulated data when facetted for carriers and non- carriers of the C allele of 
CYP1A2 C163A, which was not observed for the original structural model (data not shown).  
Discussion 
A time-to-event model successfully described the time from leflunomide initiation until 
cessation due to toxicity in 105 RA patients taking leflunomide, most of whom were 
concurrently receiving other DMARDs. The cessation hazard was best described by a step 
function of four constants, while of 23 potential covariates, only CYP1A2 C163A allele status 
significantly influenced the occurrence of toxicity. 
The analysis showed cessation hazard was highest from days 0 to 50 and 112 to 204. No 
information was available that could explain this phenomenon, although it is possible that it 
was related to the scheduling of patients clinic visits. Intensive clinical follow-up occurred in 
patients with active disease compared to less frequent visits for those in remission, and there 
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was an overall tendency to see individuals at three and six months intervals, which 
corresponds to the periods of high dropout.  Future research will aim to establish the external 
validity of the step functions, as despite describing the present population very well, the 
likelihood of describing an alternate population from a different recruitment site may be 
limited. 
Previously, the CC genotype at CYP1A2 C163A has been associated with a 9.7-fold increased 
risk of leflunomide cessation due to toxicity compared to the AC or AA genotype [p=0.002, 
odds ratio=9.708, 95%CI=2.276–41.403][11]. Analysis of C allele carriers against non-
carriers (i.e. AA vs AC + CC genotype) was conducted given the low CC genotype frequency 
(n=9; 8.6%) and previous research indicating that carriage of the C allele results in altered 
enzymatic effects[39]. In the present study carriers of one or more C alleles at CYP1A2 
C163A had a 2.29 fold increase in instantaneous cessation hazard compared to non-carriers 
(95%CI= 2.24 - 2.34, p=0.016). The C163A SNP is located in the promoter region of the 
CYP1A2 gene, and carriage of the A allele has been associated with enhanced metabolism of 
CYP1A2 substrates, particularly in cigarette smokers[11, 39]. However no association 
between smoking and leflunomide cessation was found. However, this is not surprising, as 
the rate of smoking (37.1%) in this study was small. Therefore as human liver microsome 
studies have suggested that CYP1A2, CYP2C19, and CYP3A4 are involved in the conversion 
of leflunomide to teriflunomide [40], carriers of the C allele may have lower teriflunomide 
concentrations. To date however, this has not been observed [13], which may be due to small 
sample sizes that have been unable to detect relatively small differences in teriflunomide 
concentrations that have high inter-patient variability, and/or CYP2C19 and CYP3A4 are 
able to maintain the high conversion of leflunomide to teriflunomide in individuals who carry 
a C allele at CYP1A2 C163A. Furthermore, reduced CYP1A2 activity may promote altered 
metabolism that result in significant increases in alternate toxic metabolites that are ordinarily 
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at very low concentrations, or direct toxicity from leflunomide, both of which have been 
proposed previously[12, 19]. 
In this study, we aimed to investigate potential predictors of leflunomide toxicity with a 
major focus on total and free teriflunomide concentrations. Predicted steady state trough 
concentrations at the individuals’ average dose across the study period was preferred over the 
actual teriflunomide concentration at drop-out, due to teriflunomide’s long half-life (mean ~ 
15.7 days), where approximately 8 weeks is required to achieve steady state[17, 41]. 
Instantaneous concentrations, particularly early in treatment and after dose changes, are 
highly time dependent and as such are imperfectly handled within time-to-event models, and 
are thus not a good metric to relate to toxicity between individuals on leflunomide for varying 
time lengths. Additionally, trough concentrations were used as they are subject to the 
influences of distribution effects, as well as clearance, which is the parameter solely 
responsible for the average steady state concentration. Therefore, predicted steady state 
trough concentrations were assessed, although to do this clinically, access to a population 
pharmacokinetic model, such as that used in this study[37], would be required. Despite this, 
no association was found, although we acknowledge that in this study, blood samples were 
only available from 69 of 105 participants, and given the high variability of teriflunomide 
concentrations, the population median (adjusted for the individuals ALT and FFM) is likely 
to underestimate the variability in individual concentrations within the 36 imputed subjects. 
Previously, Chan et al.[16] and Grabar et al.[13] investigated a possible relationship between 
total steady-state teriflunomide concentrations and adverse drug events in 23 and 67 RA 
patients, respectively, and found no association. These studies however were cross sectional, 
with leflunomide mostly being used as monotherapy with some participants having been on 
leflunomide for long periods and therefore selecting individuals who were tolerant of 
 This article is protected by copyright. All rights reserved. 
leflunomide. Furthermore, for many drugs free concentrations are more predictive of 
response and toxicity than total concentrations, particularly for those with a high degree of 
protein binding, such as teriflunomide, where the total concentration may be a poor surrogate 
of the free concentration[18, 20]. For the first time, predicted free steady-state teriflunomide 
concentrations have been investigated for a relationship with cessation of leflunomide due 
toxicity, although similar to previous studies, no association was found. Nor was an 
association found with the pharmacokinetic parameters (CLINT, VBODY or FU) predicted 
for each patient using our previously published model [37], or with the individual’s average 
daily leflunomide dose across the study period. 
In this study, multiple covariates were screened, of which CYP1A2 C163A genotype was 
seen to result in a statistically significant effect on leflunomide cessation rate. In the 
occurrence of multiple covariates being included on forward inclusion, a backward deletion 
procedure (p<0.005) was planned for robustness of multiple hypothesis testing, although this 
was ultimately not possible given the single significant covariate that was identified. This 
study is not only the first study to assess the association between free teriflunomide 
concentration and leflunomide cessation, it is also the first to assess leflunomide cessation 
due to toxicity through the use of a time-to-event model within NONMEM. In contrast, 
previous studies have used binary logistic regression[11, 14], which assesses hazard at 
distinct time points rather than across time, or cox proportional hazard models which are 
restricted to assuming that hazard rates change proportionally with covariates across 
time[12]. This study used a time-to-event model and found a step function with changing 
hazard across time to best describe leflunomide cessation, while conducting the analysis 
within NONMEM allowed simulation of the effect of CYP1A2 genotype, which has not been 
represented previously. Simulation highlights that although within our population the 
CYP1A2 genotype effects on leflunomide cessation was large with parameter estimates that 
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are precise (%RSE of all parameters <2.15%), as the confidence intervals of the genotypes 
overlap, in some populations the effects of CYP1A2 C163A may not be statistically 
significant with a sample size of 105 participants.  
This study did not confirm the findings of a number of other studies, including that of Grabar 
et al.[14] who previously reported an association between DHODH rs3213422 genotype and 
toxicity. As previously described there are several differences between the presented cohort 
and that studied by Grabar et al.[14], who assessed toxicity through binary logistic 
regression. This study did not confirm the finding of an association between CYP2C19 
phenotype and cessation of leflunomide due to toxicity found by Wiese et al. [12], who 
assessed toxicity within the same cohort as used in this study (although the prior study 
finalised recruiting in 2011). In the present study, recruiting completed in 2013 and there 
were 105 eligible participants compared to the 78 assessed previously. This study also 
included longer follow-up in some participants, and identified some whom had ceased 
leflunomide but were restarted at a lower dose, hence explaining the moderately lower 
cessation rate. Furthermore, participants in this study with an undeterminable CYP2C19 
phenotype (7.6%) were imputed with the mode, in contrast these participant were previously 
excluded. Wiese et al.[12] used a cox proportional hazard model including covariates 
previously associated with leflunomide cessation, assuming a cessation trend was present 
(p<0.25; current leflunomide dose, triple therapy and positive rheumatoid factor at diagnosis) 
[12]. Furthermore, Wiese et al.[12] analysed the association with CYP2C19 phenotype via a 
linear test for trend. The present study assessed cessation through a time-to-event model 
where covariates underwent a stricter inclusion criterion and categorical covariates were 
incorporated through a binary relationship. 
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Due to the observational nature of the study, the assessment of patient compliance was 
limited to reporting upon questioning at clinic visits, and although efforts were made to 
ensure all reported adverse events attributed to leflunomide were related and caused by 
leflunomide (as opposed to another DMARD or medication), certainty cannot be guaranteed. 
Also, due to the relatively small patient numbers and inability to precisely ascertain the 
relative severity of each side effect and, therefore the one primarily responsible for cessation, 
subgroup analysis of covariate effects on particular side effects was not conducted within this 
study. 
In the present study, cessation was high early after leflunomide initiation, and due to 
teriflunomide’s long half-life, plasma concentrations would be relatively low in patient 
ceasing early compared to those who continue therapy long term. Previous research has 
shown that individuals predominately cease leflunomide early due to GI side effects, 
especially with the use of the loading dose[42]; as such it appears likely these side effects are 
related to local effects rather than being linked to teriflunomide plasma concentrations. 
Therefore the subdivision of side effect appears important for future research as it may 
elucidate that side effects such as hepatotoxicity, pancytopenia and pneumonitis are related to 
high teriflunomide concentrations in the plasma, while the causes of GI side effects are 
related to local drug concentration not assessed in this study[8, 43-45]. Furthermore as 
CYP1A2 genotype has now independently been indicated as a determinant of leflunomide 
toxicity, future studies should focus upon investigating previously proposed toxic metabolites 
[12, 19], that may be directly responsible for observable concentration dependent toxicity. 
Furthermore investigating alternate significant polymorphisms within the CYP1A2 gene may 
elucidate different toxicity profiles within the leflunomide treated population, as the assessed 
polymorphisms within this study are not the only ones to be associated with altered 
enzymatic activity.  
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In conclusion, a time-to-event model describing time between leflunomide initiation and 
cessation due to side effects highlighted a significant association between CYP1A2 C163A 
genotype and toxicity. And despite the large amount of random censoring which occurred, 
the simultaneous description of censoring hazard enabled the effect to be visualised via 
simulation. No association between the assessed teriflunomide exposure metrics and toxicity 
driven cessation was found; however given the missing the blood samples from a section of 
the cohort, future research should to continue to investigate the relationship, as well as 
characterising the impact of potentially toxic metabolites. 
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Figure 1: Top panel, Kaplan-Meier plot of the observed time-to-event data (black solid 
lines) and associated 95% CI (black dashed lines), overlaid with the 1000 simulated 
populations from the covariate models median (solid red line) and the associated 95% 
CI (shaded area). Bottom panel, the original dataset and the covariate models simulated 
populations have been facetted for CYP1A2 C163A genotype. 
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Table 1: Characteristics of patients included in time-to-event analysis (n=105) 
Patient characteristics at leflunomide initiation (n=105) n (% or range) 
Female  80 (76.2) 
Age*  58.4 (19.2 – 85.9) 
Current smoker 39 (37.1) 
CYP1A2 C163A  genotype  
- AA  54 (51.4) 
- CC or AC  51 (48.6) 
CYP2C19 phenotype[12]  
- Ultra-rapid metabolisers 26 (24.8) 
- Extensive metabolisers 51 (48.6) 
- Poor and intermediate metabolisers 20 (19.0) 
- Unknown 8 (7.6) 
ABCG2 rs2231142 genotype  
- CC  87 (82.9) 
- AA or CA  18 (17.1) 
DHODH rs3213422 genotype  
- AA  24 (22.9) 
- AC  53 (50.5) 
- CC  28 (26.7) 
Carriers of DHODH Haplotype II  
- Yes 56 (53.3) 
- No 49 (46.7) 
DAS28* (n=103) 4.56 (1.48 – 7.98) 
Initiated leflunomide with a loading dose 5 (4.8) 
Initiated leflunomide while on MTX, SSZ and HCQ 59 (56.2) 
Patient characteristics at RA diagnosis  
Anti-CCP positive (n=103) 60 (58.2) 
RF positive (n=104) 67 (64.4) 
SE positive (n=101) 71 (70.3) 
Patient characteristics at cessation or censor date (n=105)  
Weight* (kg) 72.0 (40.4 – 148.5) 
Height* (cm) 163 (145 – 194) 
FFM* (kg) 44.4 (28.7 – 90.6) 
Concomitant MTX use 80 (76.1) 
- Weekly MTX dose* (mg) 20 (0 – 25) 
Concomitant SSZ use 70 (66.7) 
- Daily SSZ dose* (mg) 2000 (0 – 3000) 
Concomitant HCQ use 91 (86.7) 
- Daily HCQ dose* (mg) 400 (0 – 800) 
ALT* (units/L) 24 (6 – 931) 
AST* (units/L) 24 (11 – 432) 
CrCl*(ml/min) 77.4 (20.6 – 197.0) 
Exposure metrics (n=105)  
Daily leflunomide dose* (mg) 14.40 (6.64 – 100.00) 
Predicted total teriflunomide steady state trough concentrations* (mg/L) 20.99 (1.09 – 135.21) 
Predicted free teriflunomide steady state trough concentration* (mg/L) 0.0436 (0.0022 – 0.2879) 
FU* 0.0021 (0.0014 – 0.0029) 
CLINT* (L/day) 145.24 (6.55 – 2660.60) 
VBODY* (L) 5.09 ( 2.49 – 19.87) 
*data expressed as median (range). 
Abbreviations – disease activity score in 28 joints (DAS28), anti–citrullinated protein antibody (Anti-CCP), 
rheumatoid factor (RF), shared epitope (SE), fat free mass (FFM), methotrexate (MTX), sulfasalazine (SSZ), 
hydroxychloroquine (HCQ), alanine transaminase (ALT), aspartate transaminase (AST), creatinine clearance 
(CrCl) and fraction unbound (FU). 
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Table 2: Toxicities leading to leflunomide cessation 
Toxicity Number of patients  
Gastrointestinal (i.e. diarrhoea, nausea or vomiting) 20 
Neutropenia 7 
 Fatigue, dizziness or headaches 5 
 Elevated liver enzymes 4 
Respiratory related symptoms including pneumonitis 4 
Other** 8 
** One each of hair loss, peripheral neuropathy, muscle pain, giddiness, facial flushing, mouth 
ulcers, pulsating teeth and increased urinary frequency occurred. 
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Table 3: Parameter estimates (with bootstrap 95% CI and %RSE) for the structural 
and covariate model. The four cessation hazard constants are represented by Θ1-4 (days-
1); the five random censoring hazard constants are represented Θ5-9 (days-1); and Θ10 
represents the binary increase in         caused by the C allele of CYP1A2 rs762551 (i.e. 


















      
Θ1 days < 50  0.00232 0.00228 - 0.00237 0.98 0.00161 0.00158 - 0.00164  1.08 
Θ2 50≥days<112  0.00054 0.00052 - 0.00056 1.76 0.00034 0.00033 - 0.00035 2.12 
Θ3 112≥days<20
4 
0.00234 0.00230 - 0.00238 0.83 0.00151 0.00148 - 0.00154 1.15 





      
Θ5 days<147  0.00025 0.00024 - 0.00026 1.61 0.00024 0.00023 - 0.00025  1.73 
Θ6 147≥days<21
0  
0.00134 0.00131 - 0.00138 1.35 0.00142 0.00138 - 0.00146  1.29 
Θ7 210≥days<31
4 
0.00063 0.00061 - 0.00065 1.57 0.00068 0.00066 - 0.00070  1.49 
Θ8 314≥days<35
0 
0.00768 0.00755 - 0.00781 0.87 0.00775 0.00762 - 0.00788 0.87 
Θ9 days>350 0.0302 0.02969 - 0.03071 0.86 0.0344 0.03392 - 0.03488  0.71 
COVCYP1A2 (Θ10)  - - - 1.29 1.24 - 1.34  2.05 
 
  
 This article is protected by copyright. All rights reserved. 
Table 4: Univariate covariate screening results 
Model ∆OBJ* p-value 
Base model 0 - 
CYP1A2 C163A  genotype (dichotomous) -5.803 0.016 
ALT* -3.274 0.07 
AST* -2.849 0.091 
Use of leflunomide loading dose -2.784 0.095 
Gender -2.242 0.134 
Average daily leflunomide dose* -1.953 0.162 
DHODH Haplotype II status (dichotomous) -1.731 0.188 
SSZ dose* -1.295 0.255 
Anti-CCP positivity -1.164 0.281 
DHODH rs3213422 genotype (polychotomous) -0.862 0.353 
CYP2C19 ‘phenotype’ (polychotomous) -1.653 0.438 
Predicted free teriflunomide steady state trough concentrations*  -0.487 0.485 
Age -0.473 0.492 
Triple therapy at initiation -0.388 0.533 
MTX dose* -0.365 0.546 
HCQ dose* -0.326 0.568 
RF positivity -0.121 0.728 
The covariates of baseline DAS28, SE status, weight, height, FFM, smoking status, ABCG2 genotype, CrCl, 
FU, CLINT, VBODY and predicted total teriflunomide steady state trough concentrations did not result in any 
improvement in the OBJ. 
Abbreviations – alanine transaminase (ALT), aspartate transaminase (AST), sulfasalazine (SSZ), anti–
citrullinated protein antibody (Anti-CCP, methotrexate (MTX), hydroxychloroquine (HCQ), rheumatoid factor 
(RF), disease activity score in 28 joints (DAS28), shared epitope (SE), fat free mass (FFM), creatinine clearance 
(CrCL) and fraction unbound (FU). 
*- represent covariates that were measured at cessation or censor date 
 
